TP53 and neoplasm: To further characterize the tumor and identify potential targetable alterations, next-generation sequencing was performed by Caris® Life Sciences on the tumor from the jugular vein thrombus, revealing oncogenic mutations in the following genes but no targetable alterations: FLCN p.E464* (VAF 85%), RB1 p.R320* (VAF 78%), and TP53 p.E336fs (VAF 80%).